4.8 Article

PD1 blockade potentiates the therapeutic efficacy of photothermally-activated and MRI-guided low temperature-sensitive magnetoliposomes

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 332, Issue -, Pages 419-433

Publisher

ELSEVIER
DOI: 10.1016/j.jconrel.2021.03.002

Keywords

Anti-PD1; Magnetoliposomes; Iron oxide nanoparticles; Photothermal; Thermosensitive; Theranostics

Funding

  1. Prostate Cancer UK [CDF-12-002]
  2. Engineering and Physical Sciences Research Council (EPSRC) [EP/M008657/1]
  3. Royal Society of London [RG2014 R1]
  4. Slovenian Research Agency ARRS [Z2-9218, P2-0084, P1-0143, P3-0003, P3-0108]
  5. Marco Polo fellowship (University of Bologna)
  6. EPSRC [EP/M008657/1] Funding Source: UKRI

Ask authors/readers for more resources

This study investigates the effect of PD1 blockade in combination with photothermally-activated low temperature-sensitive magnetoliposomes (mLTSL) loaded with doxorubicin for cancer therapy. The results demonstrate the efficient drug delivery and imaging capabilities of mLTSL, as well as the potentiation of therapeutic efficacy when combined with anti-PD1 monoclonal antibody.
This study investigates the effect of PD1 blockade on the therapeutic efficacy of novel doxorubicin-loaded temperature-sensitive liposomes. Herein, we report photothermally-activated, low temperature-sensitive magnetoliposomes (mLTSL) for efficient drug delivery and magnetic resonance imaging (MRI). The mLTSL were prepared by embedding small nitrodopamine palmitate (NDPM)-coated iron oxide nanoparticles (IO NPs) in the lipid bilayer of low temperature-sensitive liposomes (LTSL), using lipid film hydration and extrusion. Doxorubicin (DOX)-loaded mLTSL were characterized using dynamic light scattering, differential scanning calorimetry, electron microscopy, spectrofluorimetry, and atomic absorption spectroscopy. Photothermal experiments using 808 nm laser irradiation were conducted. In vitro photothermal DOX release studies and cytotoxicity was assessed using flow cytometry and resazurin viability assay, respectively. In vivo DOX release and tumor accumulation of mLTSL(DOX) were assessed using fluorescence and MR imaging, respectively. Finally, the therapeutic efficacy of PD1 blockade in combination with photothermally-activated mLTSL(DOX) in CT26-tumor model was evaluated by monitoring tumor growth, cytokine release and immune cell infiltration in the tumor tissue. Interestingly, efficient photothermal heating was obtained by varying the IO NPs content and the laser power, where ondemand burst DOX release was achievable in vitro and in vivo. Moreover, our mLTSL exhibited promising MR imaging properties with high transverse r2 relaxivity (333 mM-1 s-1), resulting in superior MR imaging in vivo. Furthermore, mLTSL(DOX) therapeutic efficacy was potentiated in combination with anti-PD1 mAb, resulting in a significant reduction in CT26 tumor growth via immune cell activation. Our study highlights the potential of combining PD1 blockade with mLTSL(DOX), where the latter could facilitate chemo/photothermal therapy and MRI-guided drug delivery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available